FTC Sues Big Pharma Middlemen to Combat Skyrocketing Insulin Prices
Background of the FTC Lawsuit
The FTC has initiated legal proceedings against the major players in the pharmacy benefit manager (PBM) sector, known as the "Big Three". This strategic lawsuit aims to address the rising costs of insulin, which have severely impacted consumers across the nation.
Key Players Involved
- CVS Health’s Caremark Rx
- Cigna’s Express Scripts (ESI)
- UnitedHealth Group’s OptumRx
Implications of the Lawsuit
The implications of this lawsuit extend beyond just insulin prices; they may reshape the entire landscape of pharmaceutical pricing. The FTC’s actions could lead to more transparency in PBM practices and potentially lower costs for patients reliant on insulin therapy.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.